Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Tuesday, February 7, 2023

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Molderizer and Safe Shield

FDA emails show how vaccine leader questioned ‘hyper-accelerated’ 2021 review of Pfizer shot – Endpoints News

Vertigo in the Setting of COVID-19 Infection: A Case Report – Cureus

Vertigo in the Setting of COVID-19 Infection: A Case Report  Cureus Source link

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH – Dove Medical Press

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH  Dove Medical Press Source link

Predictors of mortality of COVID-19 in children | JMDH – Dove Medical Press

Predictors of mortality of COVID-19 in children | JMDH  Dove Medical Press Source link

Agility: Logistics Execs See 2023 Recession as "Likely" or "Certain" – PR Newswire

Agility: Logistics Execs See 2023 Recession as "Likely" or "Certain"  PR Newswire Source link

Biden prepares for State of the Union as US collects Chinese balloon debris – as it happened – The Guardian US

Biden prepares for State of the Union as US collects Chinese balloon debris – as it happened  The Guardian US Source link


Less than a week after Eisai and Biogen won accelerated approval from the FDA for their Alzheimer’s drug lecanemab, Executive Editor Drew Armstrong spoke one-on-one with Eisai’s US CEO Ivan Cheung, who also leads the company’s Alzheimer’s efforts. This transcript has been edited for brevity and clarity.

Drew Armstrong:

Welcome everybody. I am Drew Armstrong, the executive editor over at Endpoints News, and I’m exceptionally pleased to be joined by Ivan Cheung from Eisai. He runs the US business and oversees the Alzheimer’s program there. Obviously, you all have had some enormous news in the last week with the accelerated approval of Lecanemab, and congratulations on that. It’s obviously a huge moment for the field, huge moment for your company. I want to jump right in because we have 30 minutes and so much to cover. I’m incredibly excited to get this chance to talk to you. Now, that I’m in San Francisco, you’re in New Jersey. I’m sorry we aren’t able to be together in person, but tons of news from you all. You’ve gotten this accelerated approval.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.




Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Vertigo in the Setting of COVID-19 Infection: A Case Report – Cureus

Vertigo in the Setting of COVID-19 Infection: A Case Report  Cureus Source link

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH – Dove Medical Press

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH  Dove Medical Press Source link

Predictors of mortality of COVID-19 in children | JMDH – Dove Medical Press

Predictors of mortality of COVID-19 in children | JMDH  Dove Medical Press Source link

Related Articles

Vertigo in the Setting of COVID-19 Infection: A Case Report – Cureus

Vertigo in the Setting of COVID-19 Infection: A Case Report  Cureus Source link

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH – Dove Medical Press

Covid-19 Vaccine Side Effects Among Healthcare Workers | JMDH  Dove Medical Press Source link

Predictors of mortality of COVID-19 in children | JMDH – Dove Medical Press

Predictors of mortality of COVID-19 in children | JMDH  Dove Medical Press Source link